146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank

Swiss National Bank bought a new stake in shares of Applied Therapeutics, Inc. (NASDAQ:APLT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 146,900 shares of the company’s stock, valued at approximately $126,000. Swiss National Bank owned approximately 0.13% of Applied Therapeutics at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of APLT. SG Americas Securities LLC boosted its holdings in Applied Therapeutics by 169.0% during the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company’s stock valued at $35,000 after acquiring an additional 25,601 shares during the period. Private Advisor Group LLC bought a new position in shares of Applied Therapeutics in the 4th quarter worth $35,000. Y Intercept Hong Kong Ltd bought a new position in shares of Applied Therapeutics during the 3rd quarter worth approximately $149,000. Intech Investment Management LLC acquired a new position in shares of Applied Therapeutics during the third quarter worth $162,000. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Applied Therapeutics by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 313,355 shares of the company’s stock worth $268,000 after acquiring an additional 47,983 shares in the last quarter. 98.31% of the stock is owned by institutional investors.

Applied Therapeutics Price Performance

Shares of NASDAQ APLT opened at $0.52 on Monday. The firm’s 50 day simple moving average is $0.56 and its 200-day simple moving average is $3.81. Applied Therapeutics, Inc. has a 12 month low of $0.43 and a 12 month high of $10.62. The stock has a market capitalization of $60.07 million, a price-to-earnings ratio of -0.32 and a beta of 1.88.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on APLT shares. UBS Group reiterated a “neutral” rating and set a $2.00 price objective (down from $13.00) on shares of Applied Therapeutics in a research note on Monday, December 2nd. Royal Bank of Canada cut their price target on shares of Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a report on Friday, December 20th. Finally, William Blair downgraded shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Applied Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

Applied Therapeutics Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.